Natera (NTRA)

The company is best known in reproductive health for Panorama, a non-invasive prenatal test that screens fetal DNA in a maternal blood sample for certain chromosomal conditions. Natera also offers Horizon, a carrier screening test used to identify whether prospective parents carry genetic variants associated with inherited diseases that could be passed to children. These products place the company within the growing market for genetic testing used before and during pregnancy.

Beyond women’s health, Natera has built a significant presence in oncology through Signatera, a personalized molecular residual disease test. Signatera is designed to detect circulating tumor DNA in patients with a prior cancer diagnosis, helping assess whether residual disease remains after treatment and whether recurrence may be developing. This use case positions Natera in a fast-growing area of cancer monitoring where blood-based testing can complement imaging and other clinical tools.

The company also markets Prospera for transplant medicine, where molecular testing can help assess the risk of organ rejection. Across its portfolio, Natera’s distinguishing feature is the combination of laboratory assays, statistical modeling, and bioinformatics designed to detect very small genetic signals in complex samples. As a stock, Natera is influenced by test volume growth, reimbursement decisions, clinical adoption, competition in diagnostics, and regulatory developments affecting laboratory-developed tests.